Literature DB >> 318213

Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency.

G Humbert1, J P Fillastre, A Leroy, M Godin, C Van Winzum.   

Abstract

The pharmacokinetics of a single intravenous dose of 30 mg of cefoxitin/kg given to normal subjects and to patients with various degrees of chronic renal insufficiency were studied. The serum half-life of cefoxitin was correlated inversely with the rate of creatinine clearance, and the half-life increased exponentially when the creatinine clearance rate fell below 30 ml/min per 1.73 m2. The elimination of cefoxitin into urine was rapid and extensive in patients whose creatinine clearance was greater than 30 ml/min per 1.73 m2. In patients with more severe degrees of renal impairment, renal clearance of drug was diminished markedly (less than 20% of the administered dose was excreted in 4 hr as compared with greater than 60% in the former group). The clearance of cefoxitin can be increased fivefold by hemodialysis in patients with end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 318213     DOI: 10.1093/clinids/1.1.118

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis.

Authors:  A Arvidsson; G Alván; A Tranaeus; A S Malmborg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

4.  Pharmacokinetics of cefoxitin during haemofiltration.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; M Diaz Molina
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Disposition of cefoxitin in patients with ascites.

Authors:  M J Garcia; A Dominguez-Gil; F D Perez; F P Rodriguez; F D Moronta
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Cefoxitin disposition during peritoneal dialysis.

Authors:  W L Greaves; J H Kreeft; R I Ogilvie; G K Richards
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.